Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

αv integrin: a new gastrin target in human pancreatic cancer cells.

Cayrol C, Bertrand C, Kowalski-Chauvel A, Daulhac L, Cohen-Jonathan-Moyal E, Ferrand A, Seva C.

World J Gastroenterol. 2011 Oct 28;17(40):4488-95. doi: 10.3748/wjg.v17.i40.4488.

2.

Role of endogenous cholecystokinin on growth of human pancreatic cancer.

Matters GL, McGovern C, Harms JF, Markovic K, Anson K, Jayakumar C, Martenis M, Awad C, Smith JP.

Int J Oncol. 2011 Mar;38(3):593-601. doi: 10.3892/ijo.2010.886. Epub 2010 Dec 24.

3.

Crosstalk between insulin receptor and G protein-coupled receptor signaling systems leads to Ca²+ oscillations in pancreatic cancer PANC-1 cells.

Young SH, Rozengurt E.

Biochem Biophys Res Commun. 2010 Oct 8;401(1):154-8. doi: 10.1016/j.bbrc.2010.09.036. Epub 2010 Sep 16.

4.

Annexin A2 mediates up-regulation of NF-κB, β-catenin, and stem cell in response to progastrin in mice and HEK-293 cells.

Sarkar S, Swiercz R, Kantara C, Hajjar KA, Singh P.

Gastroenterology. 2011 Feb;140(2):583-595.e4. doi: 10.1053/j.gastro.2010.08.054. Epub 2010 Sep 6.

5.

Driver mutations: a roadmap for getting close and personal in pancreatic cancer.

Korc M.

Cancer Biol Ther. 2010 Sep 15;10(6):588-91. Epub 2010 Sep 24. No abstract available.

6.

Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM).

Carter H, Samayoa J, Hruban RH, Karchin R.

Cancer Biol Ther. 2010 Sep 15;10(6):582-7. Epub 2010 Oct 1.

7.

Blocking gastrin and CCK-B autocrine loop affects cell proliferation and apoptosis in vitro.

Zhou JJ, Chen ML, Zhang QZ, Zao Y, Xie Y.

Mol Cell Biochem. 2010 Oct;343(1-2):133-41. doi: 10.1007/s11010-010-0507-5. Epub 2010 Jun 18.

PMID:
20559691
8.

Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer.

Rozengurt E, Sinnett-Smith J, Kisfalvi K.

Clin Cancer Res. 2010 May 1;16(9):2505-11. doi: 10.1158/1078-0432.CCR-09-2229. Epub 2010 Apr 13.

9.

Gastrin: an acid-releasing, proliferative and immunomodulatory peptide?

Calatayud S, Alvarez A, Víctor VM.

Mini Rev Med Chem. 2010 Jan;10(1):8-19. Review.

PMID:
20380639
10.

Kinase signaling pathways as targets for intervention in pancreatic cancer.

Preis M, Korc M.

Cancer Biol Ther. 2010 May 15;9(10):754-63. Review.

PMID:
20234186
11.

A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer.

Meyer T, Caplin ME, Palmer DH, Valle JW, Larvin M, Waters JS, Coxon F, Borbath I, Peeters M, Nagano E, Kato H.

Eur J Cancer. 2010 Feb;46(3):526-33. doi: 10.1016/j.ejca.2009.11.004. Epub 2009 Dec 14.

PMID:
20006921
12.

Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study.

Richards DA, Kuefler PR, Becerra C, Wilfong LS, Gersh RH, Boehm KA, Zhan F, Asmar L, Myrand SP, Hozak RR, Zhao L, Gill JF, Mullaney BP, Obasaju CK, Nicol SJ.

Invest New Drugs. 2011 Feb;29(1):144-53. doi: 10.1007/s10637-009-9307-8. Epub 2009 Aug 28.

PMID:
19714296
13.

CCK2 receptor expression transforms non-tumorigenic human NCM356 colonic epithelial cells into tumor forming cells.

Chao C, Han X, Ives K, Park J, Kolokoltsov AA, Davey RA, Moyer MP, Hellmich MR.

Int J Cancer. 2010 Feb 15;126(4):864-75. doi: 10.1002/ijc.24845.

14.

Inactivating cholecystokinin-2 receptor inhibits progastrin-dependent colonic crypt fission, proliferation, and colorectal cancer in mice.

Jin G, Ramanathan V, Quante M, Baik GH, Yang X, Wang SS, Tu S, Gordon SA, Pritchard DM, Varro A, Shulkes A, Wang TC.

J Clin Invest. 2009 Sep;119(9):2691-701. doi: 10.1172/JCI38918. Epub 2009 Aug 3.

15.

Growth of human pancreatic cancer is inhibited by down-regulation of gastrin gene expression.

Matters GL, Harms JF, McGovern CO, Jayakumar C, Crepin K, Smith ZP, Nelson MC, Stock H, Fenn CW, Kaiser J, Kester M, Smith JP.

Pancreas. 2009 Jul;38(5):e151-61. doi: 10.1097/MPA.0b013e3181a66fdc.

16.

Phosphoinositide 3-kinases in cell migration.

Cain RJ, Ridley AJ.

Biol Cell. 2009 Jan;101(1):13-29. doi: 10.1042/BC20080079. Review.

PMID:
19055486
17.

Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy.

Lopes RB, Gangeswaran R, McNeish IA, Wang Y, Lemoine NR.

Int J Cancer. 2007 Jun 1;120(11):2344-52.

18.

G-protein-coupled receptors and cancer.

Dorsam RT, Gutkind JS.

Nat Rev Cancer. 2007 Feb;7(2):79-94. Review.

PMID:
17251915
19.

Cholecystokinin and gastrin receptors.

Dufresne M, Seva C, Fourmy D.

Physiol Rev. 2006 Jul;86(3):805-47. Review.

20.

Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials.

Chau I, Cunningham D, Russell C, Norman AR, Kurzawinski T, Harper P, Harrison P, Middleton G, Daniels F, Hickish T, Prendeville J, Ross PJ, Theis B, Hull R, Walker M, Shankley N, Kalindjian B, Murray G, Gillbanks A, Black J.

Br J Cancer. 2006 Apr 24;94(8):1107-15.

Supplemental Content

Support Center